首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1673593

免疫球蛋白市场规模、份额及成长分析（按适应症、剂型、给药途径、最终用户和地区）－2025-2032 年产业预测

Immunoglobulin Market Size, Share, and Growth Analysis, By Indication (Primary Immunodeficiency (PI), Secondary Immunodeficiency (SID)), By Form (Liquid, Lyophilized), By Route of Administration, By End-User, By Region - Industry Forecast 2025-2032

出版日期: 2025年03月01日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2023 年免疫球蛋白市场规模价值 164 亿美元，预计将从 2024 年的 175.2 亿美元成长到 2032 年的 296.5 亿美元，预测期内（2025-2032 年）的复合年增长率为 6.8%。

受免疫相关疾病盛行率上升以及诊断和治疗技术进步的推动，全球免疫球蛋白市场预计将经历显着增长。监管环境和不断增长的医疗保健支出进一步推动了这一扩张。技术创新和研发投入的增加正在提高免疫球蛋白治疗的品质和有效性。此外，新兴市场，特别是亚太和拉丁美洲，提供了巨大的成长机会。这些见解表明免疫球蛋白市场前景光明，敦促行业相关人员优先考虑技术创新、扩大生产能力并探索市场渗透策略，以满足对这些重要治疗方法日益增长的需求。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲国家
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前 5 家公司对比
主要企业市场定位（2024年）
主要市场参与者所采用的策略
近期市场趋势
公司市场占有率分析（2024 年）
主要企业简介
- 公司详细信息
- 产品系列分析
- 公司分部份额分析
- 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

Grifols（Spain）
CSL Limited（Australia）
Octapharma（Switzerland）
Kedrion Biopharma（Italy）
Biotest AG（Germany）
LFB Group（France）
Shanghai RAAS Blood Products（China）
China Biologic Products Holdings（China）
Baxter International Inc.（USA）
Takeda Pharmaceutical Company（Japan）
Sanquin（Netherlands）
Bio Products Laboratory（UK）
Emergent BioSolutions（USA）
ADMA Biologics（USA）
Kamada Ltd.（Israel）
Green Cross Corporation（South Korea）
SK Plasma（South Korea）
Hualan Biological Engineering Inc.（China）
Beijing Tiantan Biological Products（China）
Shire Plc（UK）

结论和建议

简介目录

Product Code: SQMIG35G2149

Immunoglobulin Market size was valued at USD 16.4 billion in 2023 and is poised to grow from USD 17.52 billion in 2024 to USD 29.65 billion by 2032, growing at a CAGR of 6.8% during the forecast period (2025-2032).

The global Immunoglobulin market is poised for considerable growth, fueled by the rising incidence of immunological disorders and advancements in diagnostic and therapeutic techniques. A supportive regulatory landscape and increasing healthcare expenditures further bolster this expansion. Innovations and heightened investment in research and development are enhancing the quality and effectiveness of Immunoglobulin therapies. Additionally, emerging markets, notably in the Asia-Pacific and Latin America regions, offer substantial opportunities for growth. These insights suggest a promising outlook for the Immunoglobulin market, encouraging industry stakeholders to prioritize innovation, scale up capacities, and explore market penetration strategies to satisfy the growing demand for these vital therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Immunoglobulin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Immunoglobulin Market Segments Analysis

Global Immunoglobulin Market is segmented by Indication, Form, Route of Administration, End-User and region. Based on Indication, the market is segmented into Primary Immunodeficiency (PI), Secondary Immunodeficiency (SID), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain Barre Syndrome, Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN) and Others. Based on Form, the market is segmented into Liquid and Lyophilized. Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous, Intramuscular. Based on End-User, the market is segmented into Hospitals, Clinics, Homecare and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Immunoglobulin Market

A significant driver of the global Immunoglobulin market is the rising incidence of immunological disorders. Immunoglobulins are essential for treating a variety of conditions, including primary immunodeficiencies, autoimmune diseases, and infectious diseases. The growing prevalence of these disorders, enhanced by better diagnostic methods and increased awareness, is driving the demand for Immunoglobulin therapies. Contributing factors include genetic susceptibility, environmental influences, and lifestyle shifts that lead to a higher occurrence of immunological issues worldwide. Moreover, improvements in healthcare infrastructure, greater access to medical services, and increasing healthcare spending are also pivotal in propelling the market's expansion.

Restraints in the Immunoglobulin Market

A major constraint faced by the global Immunoglobulin market is the steep cost associated with Immunoglobulin therapies. The intricate processes required for the production, purification, and storage of these therapies contribute to elevated manufacturing expenses, which in turn lead to higher prices for patients and healthcare systems. This financial barrier is particularly pronounced in developing nations where healthcare resources are limited and affordability is a critical concern. Additionally, reimbursement challenges and restricted insurance coverage further exacerbate the financial strain on individuals seeking these therapies. Consequently, it is vital to explore strategies aimed at minimizing production costs, fostering market competition, and enhancing the availability of affordable Immunoglobulin treatments to improve patient access and care.

Market Trends of the Immunoglobulin Market

The global Immunoglobulin market is witnessing a prominent trend characterized by a surge in the adoption of intravenous immunoglobulin (IVIG) therapy. This therapy, crucial for patients with immunodeficiency disorders, autoimmune diseases, and specific neurological conditions, has gained traction due to its proven efficacy and the heightened awareness of its therapeutic benefits among healthcare professionals and patients alike. Innovations in production technologies, enhanced product safety standards, and the broadening scope of IVIG indications are fueling this adoption. Concurrently, the rising incidence of immunological disorders and an aging population are further propelling the demand for Immunoglobulin products, solidifying IVIG therapy's pivotal role in modern medicine.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Patent Analysis

Global Immunoglobulin Market Size by Indication & CAGR (2025-2032)

Market Overview
Primary Immunodeficiency (PI)
Secondary Immunodeficiency (SID)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Guillain Barre Syndrome
Immune Thrombocytopenic Purpura (ITP)
Multifocal Motor Neuropathy (MMN)
Others

Global Immunoglobulin Market Size by Form & CAGR (2025-2032)

Market Overview
Liquid
Lyophilized

Global Immunoglobulin Market Size by Route of Administration & CAGR (2025-2032)

Market Overview
Intravenous
Subcutaneous

Global Immunoglobulin Market Size by End-User & CAGR (2025-2032)

Market Overview
Hospitals
Clinics
Homecare
Others

Global Immunoglobulin Market Size & CAGR (2025-2032)

North America (Indication, Form, Route of Administration, End-User)
- US
- Canada
Europe (Indication, Form, Route of Administration, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Indication, Form, Route of Administration, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Indication, Form, Route of Administration, End-User)
- Brazil
- Rest of Latin America
Middle East & Africa (Indication, Form, Route of Administration, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Grifols (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CSL Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Octapharma (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kedrion Biopharma (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biotest AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LFB Group (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shanghai RAAS Blood Products (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
China Biologic Products Holdings (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxter International Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanquin (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio Products Laboratory (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Emergent BioSolutions (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ADMA Biologics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kamada Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Green Cross Corporation (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SK Plasma (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hualan Biological Engineering Inc. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Beijing Tiantan Biological Products (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shire Plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments